<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471717</url>
  </required_header>
  <id_info>
    <org_study_id>AI472-004</org_study_id>
    <secondary_id>INX-189-004</secondary_id>
    <nct_id>NCT01471717</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects</brief_title>
  <acronym>INX-189-004</acronym>
  <official_title>A Phase Ib, Single-Center, Randomized, Two-Sequence, Placebocontrolled, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the potential for a pharmacokinetic drug-drug interaction&#xD;
      between INX-08189 and Victrelis, a Direct Acting Antiviral (DAA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, placebo-controlled study in thirty-two 18 to 55 year&#xD;
      old, male and female, healthy adult volunteers.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      Pharmacokinetic&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of INX-08189 and INX-08032 when&#xD;
           INX-08189 is dosed alone as compared to when dosed in combination with Victrelis&#xD;
&#xD;
        -  To characterize the PK profile of Victrelis when dosed alone as compared to when dosed&#xD;
           in combination with INX-08189&#xD;
&#xD;
      Safety&#xD;
&#xD;
      - To evaluate the safety of INX-08189 and Victrelis when dosed alone and when dosed in&#xD;
      combination&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of INX-08189, INX-08032, and Victrelis when dosed alone and in combination</measure>
    <time_frame>INX-08189: C1: Days 4 &amp; 7; C2: Day 7 pre-dose &amp; 15, 30, &amp; 45 minutes, &amp; 1, 2, 3, 4, 6, 8, 10, 12, 16, &amp; 24 hours after dosing. Victrelis: C2: Days 2 &amp; 7; C1: Day 7 pre-dose &amp; 0.5, 1, 2, 3, 4, 6, &amp; 8 hours after AM dose. Up to 72 hours after last dose.</time_frame>
    <description>PK parameters of INX-08189, INX-08032, and Victrelis when dosed alone and in combination: maximum observed plasma concentration (Cmax), time at which Cmax is observed (Tmax), plasma concentration at the end of dosing interval (Ctau), area under the plasma concentration-time curve from time 0 to the end of dosing interval (AUC0-tau), elimination half-life (t1/2), apparent oral clearance (CL/F), and apparent oral volume of distribution (Vz/F), as applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters, including adverse event, concurrent medication, clinical laboratory, ECG, PE, and VS assessments</measure>
    <time_frame>Study Day 1 to 8, and Study Day 14</time_frame>
    <description>Safety will be monitored by PEs, VS, clinical laboratory tests (including blood chemistry, CBC with differential, Troponin I, creatinine phosphokinase, and urinalysis), ECGs, and AE assessments.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>C 1:INX-08189 50 mg qd X 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1: INX-08189 / Victrelis 800 mg TID X 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2: Victrelis 800 mg TID x 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C 2:Victrelis 800 mg TID with INX-08189 50 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1: Placebo with Victrelis 800 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C 2: Victrelis 800 mg with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189 50 mg QD X 5 days</intervention_name>
    <description>Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.</description>
    <arm_group_label>C 1:INX-08189 50 mg qd X 5 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INX-08189 / Victrelis 800 mg TID X three days</intervention_name>
    <description>Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)</description>
    <arm_group_label>C1: INX-08189 / Victrelis 800 mg TID X 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victrelis 800 mg TID x 3 days</intervention_name>
    <description>In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).</description>
    <arm_group_label>C2: Victrelis 800 mg TID x 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victrelis 800 mg TID with INX-08189 50 mg QD</intervention_name>
    <description>Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).</description>
    <arm_group_label>C 2:Victrelis 800 mg TID with INX-08189 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo with Victrelis 800 mg</intervention_name>
    <description>During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.</description>
    <arm_group_label>C1: Placebo with Victrelis 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: Victrelis 800 mg with Placebo</intervention_name>
    <description>During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.</description>
    <arm_group_label>C 2: Victrelis 800 mg with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet the following criteria at the Screening Visit (Visit1), in order to be&#xD;
        eligible for study drug administration at Study Day 0 (Visit 3):&#xD;
&#xD;
          1. Must be a healthy male or female between 18 and 55 years of age (inclusive) with body&#xD;
             mass index (BMI) between 18 and 30 kg/m2 (inclusive), and weigh â‰¥ 50 kg at the time of&#xD;
             signing the informed consent;&#xD;
&#xD;
          2. Capable of giving written informed consent that includes compliance with the&#xD;
             requirements and restrictions listed in the consent form. Signed informed consent must&#xD;
             be on file prior to screening procedures;&#xD;
&#xD;
          3. Subject is able to understand and comply with the protocol requirements, instructions&#xD;
             and restrictions;&#xD;
&#xD;
          4. Must be a non-tobacco user for at least 3 months prior to selection;&#xD;
&#xD;
          5. Healthy on the basis of physical examination, medical history, vital signs,&#xD;
             electrocardiogram and clinical laboratory tests at screening;&#xD;
&#xD;
          6. Women must be postmenopausal for at least 2 years or be surgically sterile with&#xD;
             complete hysterectomy or bilateral oophorectomy, and not be pregnant nor&#xD;
             breastfeeding;&#xD;
&#xD;
          7. Male subjects, who are not surgically sterile with vasectomy, must agree to use a&#xD;
             double barrier method of birth control, such as, a condom plus spermicidal agent&#xD;
             (foam/gel/film/cream/suppository). This criterion must be followed from the time of&#xD;
             the first dose of study medication until 30 days after the last dose of medication.&#xD;
             Male subjects cannot donate sperm during the study and for 3 months after receiving&#xD;
             the last dose of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must NOT meet the following criteria at the Screening Visit (Visit1), in order to&#xD;
        be eligible for study drug administration at Study Day 0 (Visit 3):&#xD;
&#xD;
          1. Infection with Hepatitis A, B or C Virus;&#xD;
&#xD;
          2. Infection with the Human Immunodeficiency Virus (HIV);&#xD;
&#xD;
          3. History of or any current medical condition which could impact the safety of the&#xD;
             participant in the study;&#xD;
&#xD;
          4. Current active or underlying gastrointestinal, cardiovascular, neurologic,&#xD;
             psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious&#xD;
             disease;&#xD;
&#xD;
          5. Clinically significant abnormalities on centrally read ECG;&#xD;
&#xD;
          6. Currently significant diarrhea, gastric stasis, or constipation that in the&#xD;
             investigator's opinion could influence drug absorption or bioavailability;&#xD;
&#xD;
          7. Safety laboratory abnormalities at screening which are clinically significant, or&#xD;
             absolute neutrophil count of &lt; 1800 cells/mm3, or platelet count &lt; 130,000 cells/mm3,&#xD;
             or hemoglobin &lt; 12 g/dl for women and &lt; 13 g/dl for men;&#xD;
&#xD;
          8. Women of child bearing potential;&#xD;
&#xD;
          9. Pregnant or breastfeeding;&#xD;
&#xD;
         10. Current abuse of alcohol or illicit drugs, or history of alcohol or illicit drug abuse&#xD;
             within the preceding two years;&#xD;
&#xD;
         11. A positive urine drug test at screening;&#xD;
&#xD;
         12. Consumption of more than 2 units of alcoholic beverages per day or more than 14 units&#xD;
             per week (1 unit of alcohol equals 1 glass of beer, 1 glass of wine, 25ml shot of 40%&#xD;
             spirit), consumption of alcohol 72 hours before or after study medication intake,&#xD;
             consumption of an average of more than five 240 ml servings of coffee or other&#xD;
             caffeinated beverages per day;&#xD;
&#xD;
         13. Use of chronic prescription medications within 3 months, acute prescription&#xD;
             medications within 14 days, or systemic over-the-counter (OTC) medications, including&#xD;
             vitamins, within 7 days of starting the study;&#xD;
&#xD;
         14. Received an investigational drug or vaccine within 30 days or 5 half lives, whichever&#xD;
             is longer, from the receipt of a small molecule or 90 days or 5 half lives, whichever&#xD;
             is longer, from the receipt of a large biological molecule prior to Study Day 0, or&#xD;
             used an investigational medical device within 30 days prior to Study Day 0, or having&#xD;
             participated previously in a study with INX-08189.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Campaneria, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research, LLC</name>
      <address>
        <city>St Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>INX08189</keyword>
  <keyword>Victrelis</keyword>
  <keyword>Inhibitex</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

